Preview

Педиатрическая фармакология

Расширенный поиск

Коронавирусная инфекция (COVID-19) у детей (состояние на апрель 2020)

https://doi.org/10.15690/pf.v17i2.2094

Аннотация

Дорогие друзья, коллеги!

Прошло не так много времени с момента опубликования моего прошлого обзора, но появилось так много новостей, что они поменяли некоторые наши представления о болезни и о методах ее лечения самым кардинальным образом! И это интересно как с медицинской, так и с философской точки зрения. С философской — потому что 1–2 мес нашей прошлой, «доковидной», жизни пролетали как одно мгновение, а сегодня — это огромный путь, который мы проделываем, наблюдая за новой инфекцией и продолжая искать эффективные средства ее сдерживания и контроля. А о медицинской составляющей мы сейчас и поговорим.

Об авторе

Л. С. Намазова-Баранова
Научно-исследовательский институт педиатрии и охраны здоровья детей ЦКБ РАН; Российский национальный исследовательский медицинский университет им. Н.И. Пирогова; Белгородский государственный национальный исследовательский университет
Россия

Намазова-Баранова Лейла Сеймуровна, доктор медицинских наук, профессор, академик РАН, заведующая кафедрой факультетской педиатрии педиатрического факультета ФГБОУ ВО «РНИМУ им. Н.И. Пирогова» Минздрава России, руководитель НИИ педиатрии и охраны здоровья детей ЦКБ РАН Министерства науки и высшего образования РФ, президент Союза педиатров России, профессор Королевского колледжа терапевтов Ирландии

119333, Москва, ул. Фотиевой, д. 10, тел.: +7 (499) 400-47-33


Раскрытие интересов:

получение исследовательских грантов и гонораров за научное консультирование и чтение лекций от фармацевтической компании ООО «МСД Фармасьютикалс», ООО «ФОРТ», ООО «Шайер Биотех Рус», ООО «Пфайзер Инновации», ООО «Санофи-авентис групп», ООО «ЭббВи», ООО «Пьер Фабр»



Список литературы

1. Jiang S, Shi Z, Shu Y, et al. A distinct name is needed for the new coronavirus. Lancet. 2020;395(10228):949. doi: 10.1016/S0140-6736(20)30419-0.

2. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage В beta-coronaviruses. Nat Microbiol. 2020;5(4):562–569. doi: 10.1038/s41564-020-0688-y.

3. Dong Y, Мо Х, Нu Y, et al. Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China. Pediatrics. 2020. doi: 10.1542/peds.2020-0702

4. Du Z, Xu X, Wu Y, et al. Serial Interval of COVID-19 among Publicly Reported Confirmed Cases. Emerg Infect Dis. 2020;26(6):1341–1343. doi: 10.3201/eid2606.200357.

5. Wu P, Duan F, Luo C, et al. Characteristics of ocular findings of patients with Coronavirus Disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmology. 2020;138(5):575–578. doi: 10.1001/jamaophthalmol.2020.1291.

6. Shen K, Yang Y. Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue. World J Pediatr. 2020;1–3. doi: 10.1007/s12519-020-00344-6.

7. Molloy EJ, Bearer CF. COVID-19 in children and altered inflammatory responses. Pediatr Res. 2020. doi: 10.1038/s41390-020-0881-y.

8. Cristiani L, Mancino E, Matera L, et al. Will children reveal their secret? The coronavirus dilemma. Eur Respir J. 2020;55(4):2000749. doi: 10.1183/13993003.00749-2020.

9. Xu Y, Li X, Zhu B, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med. 2020;26(4):502–505. doi: 10.1038/s41591-020-0817-4.

10. Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533–535. doi: 10.1038/s41423-020-0402-2.

11. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034. doi: 10.1016/S0140-6736(20)30628-0.

12. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect. 2020;104(3):246–251. doi: 10.1016/j.jhin.2020.01.022.

13. Van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med. 2020;82(16):1564–1567. doi: 10.1056/NEJMc2004973.

14. Nishiura H, Linton NM, Akhmetzhanov AR. Serial interval of novel coronavirus (COVID-19) infections. Int J Infect Dis. 2020;93:284–286. doi: 10.1016/j.ijid.2020.02.060.

15. Du Z, Xu X, Wu Y, et al. Serial Interval of COVID-19 among Publicly Reported Confirmed Cases. Emerg Infect Dis. 2020;26(6):1341–1343. doi: 10.3201/eid2606.200357.

16. Кат KQ, Yung CF, Cui L, et at. A Well Infant with Coronavirus Disease 2019 (COVID-19) with High Viral Load. Clin Infect Dis. 2020. doi: 10.1093/cid/ciaa201.

17. Cai J, Xu J, Lin D, et al. A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis. 2020. doi: 10.1093/cid/ciaa198.

18. Qiu H. Wu J, Hong L, et al. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis. 2020;S1473-3099(20)30198-5. doi: 10.1016/S1473-3099(20)30198-5.

19. Xu Y, Li X, Zhu B, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med. 2020;26(4):502–505. doi: 10.1038/s41591-020-0817-4.

20. Young BE, Ong SW, Kalimuddin S, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA. 2020;323(15):1488–1494. doi: 10.1001/jama.2020.3204.

21. Cao Q, Chen YC, Chen CL, Chiu CH. SARS-CoV-2 infection in children: Transmission dynamics and clinical characteristics. J Formos Med Assoc. 2020;119(3):670–673. doi: 10.1016/j.jfma.2020.02.009.

22. Su L, Ma X, Yu H, et al. The different clinical characteristics of corona virus disease cases between children and their families in China — the character of children with COVIO-19. Emerg Microbes Infect. 2020;9(1):707–713. doi: 10.1080/22221751.2020.1744483.

23. Ма Х, Su L, Zhang Y, et al. Do children need a longer time to shed SARS-CoV-2 in stool than adults? J Microbiol Immunol Infect. 2020. doi: 10.1016/j.jmii.2020.03.010.

24. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382(12):1177–1179. doi: 10.1056/NEJMc2001737.

25. Zeng H, Хu С, Fan J, et al. Antibodies in infants вorn to mothers with COVID-19 pneumonia. JAMA. 2020;323(18):1848–1849. doi: 10.1001/jama.2020.4861.

26. Dong L, Tian J, He S, et al. Possible vertical transmission of SARS-CoV-2 from an infected mother to her newborn. JAMA. 2020;323(18):1846–1848. doi: 10.1001/jama.2020.4621.

27. Coronavirus disease (COVID-2019) situation reports. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.

28. Таgarro A, Epalza С, Santos М, et al. Screening and severity of Coronavirus Disease 2019 (COVID-19) in children in Madrid, Spain. JAMA Pediatr. 2020;e201346. doi: 10.1001/jamapediatrics.2020.1346.

29. Wei M, Yuan J, Liu Y, et al. Novel Coronavirus infection in hospitalized infants under 1 year of age in China. JAMA. 2020;323(13):1313–1314. doi: 10.1001/jama.2020.2131.

30. Lu X, Zhang L, Du H, et al. SARS-CoV-2 Infection in Children. N Engl J Med. 2020;382(17):1663–1665. doi: 10.1056/NEJMc2005073.

31. Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the lcelandic Population. N Engl J Med. 2020;NEJMoa2006100. doi: 10.1056/NEJMoa2006100.

32. Worcester S. COVID-19 characteristics differ in children vs adults. 2020. Available at: https://www.medscape.com/viewarticle/926805.

33. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5.

34. Zhu N, Zhang D, Wang W, et al. A novel Coronavirus from patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi: 10.1056/NEJMoa2001017.

35. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi: 10.1056/NEJMoa2002032.

36. Baez D. Clinical findings of 6 children with COVID-19, risks factors associated with COVID-19 death, and detection of SARS-CoV-2 in different clinical specimens. 2020.

37. Lu X, Liqiong ZL, Du H, et al. SARS-CoV-2 Infection in Children. N Engl J Med. 2020;382(17):1663–1665. doi: 10.1056/NEJMc2005073.

38. Chan JF, Yuan S, Kok K, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–523. doi: 10.1016/S0140-6736(20)30154-9.

39. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi: 10.1016/S0140-6736(20)30566-3.

40. Zhang J, Dong X, Cao Y, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020. doi: 10.1111/all.14238.

41. Boulos MN, Geraghty EM. Geographical tracking and mapping of coronavirus disease COVID-19/severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic and associated events around the world: how 21st century GIS technologies are supporting the global fight against outbreaks and epidemics. Int J Health Geogr. 2020;19(1):8. doi: 10.1186/s12942-020-00202-8.

42. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323(18):1843–1844. doi: 10.1001/jama.2020.3786.

43. Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020;395(10226):809–815. doi: 10.1016/S0140-6736(20)30360-3.

44. TheDailyStar. Coronavirus suspicion: 7-month-old baby sent to Dhaka from isolation ward in Kushtia. 2020. Available at https://www.thedailystar.net/coronavirus-suspicion-in-kushtia-7-month-old-baby-isolation-ward-1886209.

45. Zeng L, Xia S, Yuan W, et al. Neonatal early-onset infection with SARS-CoV-2 in 33 neonates воrn to mothers with COVID-19 in Wuhan, China. JAMA Pediatrics. 2020;e200878. doi: 10.1001/jamapediatrics.2020.0878.

46. Xia W, Shao J, Guo Y, et al. Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults. Pediatr Pulmonol. 2020;55(5):1169–1174. doi: 10.1002/ppul.24718.

47. Chen ZM, Fu JF, Shu Q, et al. Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus. World J Pediatr. 2020;1–7. doi: 10.1007/s12519-020-00345-5.

48. Liu W, Zhang Q, Chen J, et al. Detection of Covid-19 in Children in Early January 2020 in Wuhan, China. N Engl J Med. 2020;382(14):1370–1371. doi: 10.1056/NEJMc2003717.

49. Zheng F, Liao C, Fan QH, et al. Clinical characteristics of children with Coronavirus Disease 2019 in Hubei, China. Curr Med Sci. 2020;40(2):275–280. doi: 10.1007/s11596-020-2172-6.

50. Marzano AV, Genovese G, Fabbrocini G, et al. Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients. J Am Acad Dermatol. 2020;S0190-9622(20)30657-5. doi: 10.1016/j.jaad.2020.04.044.

51. Genovese G, Colonna C, Marzano AV. Varicella-like exanthem associated with COVID-19 in an 8-year-old girl: a diagnostic clue? Pediatr Dermatol. 2020. doi: 10.1111/pde.14201.

52. Gao Y, Li T, Han M, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020;0.1002/jmv.25770. doi: 10.1002/jmv.25770.

53. Li W, Cui H, Li K, et al. Chest computed tomography in children with COVID-19 respiratory infection. Pediatr Radiol. 2020;50(6):796–799. doi: 10.1007/s00247-020-04656-7.

54. Henry BM, Lippi G, Plebani M. Laboratory abnormalities in children with novel coronavirus disease 2019. Clin Chem Lab Med. 2020; j/cclm.ahead-of-print/cclm-2020-0272/cclm-2020-0272.xm. doi: 10.1515/cclm-2020-0272.

55. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi: 10.1016/S0140-6736(20)30211-7.

56. Guo L, Ren L, Yang S, et at. Profiting early humorat response to diagnose novel Coronavirus Disease (COVID-19). lin Infect Dis. 2020;ciaa310. doi: 10.1093/cid/ciaa310.

57. Cui Y, Tian M, Huang D, et al. A 55-Day-Old Female Infant infected with COVID 19: presenting with pneumonia, liver injury, and heart damage. J Infect Dis. 2020;221(11):1775–1781. doi: 10.1093/infdis/jiaa113.

58. Turner D, Huang Y, Martin-de-Carpi J, et al. COVID-19 and paediatric inflammatory bowel diseases: global experience and provisional guidance (March 2020) from the Paediatric IBD Porto group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2020. doi: 10.1097/MPG.0000000000002729.

59. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–523. doi: 10.1016/S0140-6736(20)30154-9.

60. Намазова-Баранова Л.С., Баранов А.А. Коронавирусная инфекция у детей (состояние на февраль 2020) // Педиатрическая фармакология. — 2020. — Т.17. — №1. — С. 7–11. doi: https://doi.org/10.15690/pf.v17i1.2076.

61. D’Antiga L. Coronavimses and immunosuppressed patients. The facts during the third epidemic. Liver Transpl. 2020. doi: 10.1002/lt.25756.

62. Rasmussen SA, Smulian JC, Lednicky JA, et al. Coronavirus Disease 2019 (COVID-19) and Pregnancy: What obstetricians need to know. Am J Obstet Gynecol. 2020;222(5):415–426. doi: 10.1016/j.ajog.2020.02.017.

63. Li Y, Zhao R, Zheng S, et al. Lack of Vertical Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, China. Emerg Infect Dis. 2020;26(6):1335–1336. doi: 10.3201/eid2606.200287.

64. Lu Q, Shi Y. Coronavirus disease (COVID-19) and neonate: What neonatologist need to know. J Med Virol. 2020;10.1002/jmv.25740. doi: 10.1002/jmv.25740.

65. Zhu H, Wang L, Fang C, et al. Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. Transl Pediatr. 2020;9(1):51–60. doi: 10.21037/tp.2020.02.06.

66. FitzGerald GA. Misguided drug advice for COVID-19. Science. 2020;367(6485):1434. doi: 10.1126/science.abb8034.

67. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222. doi: 10.1038/s41467-019-13940-6.

68. Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020;64(5):e00399-20. doi: 10.1128/AAC.00399-20.

69. Yao X, Ye F, Zhang M, et al. In Vitro Antiviral activity and projection of optimized dosing design of Hydroxychloroquine for the treatment of severe acute respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;ciaa237. doi: 10.1093/cid/ciaa237.

70. Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;NEJMoa2007016. doi: 10.1056/NEJMoa2007016.

71. Сао В, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–1799. doi: 10.1056/NEJMoa2001282.

72. Gautret P, Lagier J, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;105949. doi: 10.1016/j.ijantimicag.2020.105949.

73. Chang R, Sun W. Repositioning chloroquine as ideal antiviral prophylactic against COVID-19 — time is now. 2020;2020030279. https://doi.org/10.20944/preprints202003.0279.v1.

74. Advisory on the use of hydroxy-chloroquine as prophylaxis for SARS-CoV-2 infection. Recommendation. 2020. Available at: https://www.mohfw.gov.in/pdf/AdvisoryontheuseofHydroxychloroquinasprophylaxisforSARSCoV2infection.pdf.

75. Velthuis AJ, van den Worm SH, Sims AC, et al. Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog. 2010;6(11):e1001176. doi: 10.1371/journal.ppat.1001176.

76. Hoffmann M, Kleine-Weber H. Schroeder S, et al. SARS-CoV-2 dCell entry depens on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;271–280.e8. doi: 10.1016/j.cell.2020.02.052.

77. Yamamoto M, Matsuyama S, Li X, et al. Identification of nafamostat as a potent inhibitor of middle east respiratory syndrome Coronavirus S Protein-Mediated membrane fusion using the split-protein-based cell-cell fusion assay. Antimicrob Agents Chemother. 2016;60(11):6532–6539. doi: 10.1128/AAC.01043-16.


Рецензия

Для цитирования:


Намазова-Баранова Л.С. Коронавирусная инфекция (COVID-19) у детей (состояние на апрель 2020). Педиатрическая фармакология. 2020;17(2):85-94. https://doi.org/10.15690/pf.v17i2.2094

For citation:


Namazova-Baranova L.S. Coronaviral Infection (COVID-19) in Children (Situation on April 2020). Pediatric pharmacology. 2020;17(2):85-94. (In Russ.) https://doi.org/10.15690/pf.v17i2.2094

Просмотров: 938


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution-NonCommercial 4.0 International.


ISSN 1727-5776 (Print)
ISSN 2500-3089 (Online)